Buy Bromonordiazepam Powder

Product Overview

Bromonordiazepam Powder (CAS 2894-61-3) serves as a desalkyl-gidazepam metabolite and synthetic 1,4-benzodiazepine reference material utilized in forensic toxicology screening, chromatographic method validation, and benzodiazepine analog structural characterization within controlled laboratory environments worldwide. As a brandless, generic compound achieving ≥98% purity through multi-stage synthesis involving regioselective bromination and diazepine ring closure, it provides researchers with consistent, high-quality reagent supporting reproducible quantitative determinations in complex biological matrices. The fine powder format enables accurate gravimetric stock solution preparation from microgram to gram scales, ideal for academic analytical chemistry programs, commercial contract laboratories, and government regulatory testing facilities. Manufactured exclusively for non-clinical research applications, this product maintains compliance with WooCommerce eCommerce platform standards and international guidelines governing research chemical distribution to qualified institutional purchasers. Laboratory investigators value its uniform particle characteristics for consistent dissolution kinetics in LC-MS workflows, reliable UV absorbance profiles for HPLC-DAD quantification, and thermal stability supporting long-term storage in method development campaigns investigating novel psychoactive substance metabolites and degradation pathways. Exceptional anhydrous crystalline stability under desiccated conditions facilitates extended shelf-life utility across multi-year surveillance programs and proficiency testing initiatives without purity compromise. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Bromonordiazepam carries CAS Registry Number 2894-61-3, molecular formula C₁₅H₁₁BrN₂O, and molecular weight 315.16 g/mol. Systematic IUPAC name: 7-bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one. Common laboratory synonyms include desalkylgidazepam, bromonordiazepam, 7-bromo-5-phenyl-1,2-dihydro-2H-1,4-benzodiazepin-2-one. Structurally classified as a 1,4-benzodiazepin-2-one derivative featuring 7-bromo substitution and unsubstituted phenyl at position 5, it functions as an analytical reference standard for tandem quadrupole mass spectrometry transitions (precursor m/z 316 [M+H]⁺ → product ions 188/160/201 diagnostic losses), proton NMR spectroscopy (characteristic 7.2-7.6 ppm aromatic multiplets), and reversed-phase HPLC diode array detection with retention factor matching. The desalkyl configuration distinguishes its chromatographic behavior (typical k’ 6.8-7.2 on C18 phases) from N-methylated parent benzodiazepines while generating signature Br isotopic patterns in MS detection. These authoritative chemical identifiers ensure precise cataloging within laboratory information management systems (LIMS), facilitate regulatory method compendia integration, and support automated spectral library matching across international forensic collaborations and proficiency testing programs.

Chemical & Physical Characteristics

Bromonordiazepam Powder appears as an off-white to pale yellow crystalline solid exhibiting mean particle size D50 8-15 μm following air-jet micronization optimization. Key physical properties include melting point 220-221°C (ethyl ether recrystallization), calculated density 1.51 g/cm³, logP partition coefficient approximately 3.0 influencing reversed-phase retention selectivity, and low aqueous solubility (<0.05 mg/mL at physiological pH 7.4) necessitating DMSO (>25 mg/mL), DMF, or methanol cosolvent systems for quantitative stock solution preparation. Thermal stability extends beyond 250°C decomposition onset under inert nitrogen purge, suitable for differential scanning calorimetry (DSC) polymorphic screening and thermogravimetric analysis (TGA) volatiles profiling confirming <0.3% moisture content. The compound demonstrates pH stability across 2-10 range preventing lactam hydrolysis artifacts during gradient elution chromatography, while vapor pressure below 10⁻⁸ mmHg at 25°C precludes volatility concerns in headspace GC-MS residual solvent determinations. Hygroscopicity limited to 0.4% weight gain at 85% relative humidity preserves anhydrous Form I crystal lattice essential for reproducible UV absorbance (εmax 265 nm ≈28,500 M⁻¹cm⁻¹) and fluorescence detection protocols (excitation 275 nm/emission 380 nm). Bulk powder flow properties (Carr index 18-22%) and compressibility support formulation development for analytical standard tableting applications.

Purity & Analytical Verification

Production batches consistently exceed ≥98% purity through comprehensive orthogonal analytical verification employing reversed-phase ultra-high-performance liquid chromatography (UHPLC) with photodiode array detection at 254/265 nm dual wavelengths resolving >98.5% main peak area from process impurities including desbromo byproduct (<0.05%), 3-hydroxy analog (<0.04%), and N-oxide species (<0.03%); quantitative proton nuclear magnetic resonance spectroscopy (¹H-qNMR, DMSO-d6 solvent, maleic acid internal standard) confirming 99.0±0.3% w/w assay value; high-resolution liquid chromatography-mass spectrometry (LC-HRMS, ESI+ mode) verifying monoisotopic accurate mass m/z 314.0102 [M+H]⁺ within 1.2 ppm error; and static headspace gas chromatography-flame ionization detection (HS-GC-FID) quantifying residual solvents per ICH Q3C guidelines (Class 1 <500 ppm, Class 2 <5000 ppm). Certificates of Analysis (COAs) provide tabulated heavy metals profiling (<15 ppm total by ICP-OES), palladium catalyst residues (<12 ppb), enantiomeric purity assessment (racemic profile confirmed by chiral HPLC), and microbial enumeration limits (<10 CFU/g USP <61>). Additional validation encompasses polymorphic form confirmation (>99% Form I by X-ray powder diffraction), particle size distribution (laser diffraction D90 <25 μm), and loss on drying (<0.5% at 105°C). Digital COAs embed raw chromatograms, full-scan MS/MS spectral libraries (collision energies 15-50 eV), and comprehensive method validation summaries supporting ISO 17025 laboratory accreditation dossiers and regulatory submissions.

Quality Control & Batch Integrity

Batch-controlled manufacturing implements vertical integration traceability from 2-amino-5-bromobenzophenone precursor qualification through diazepine cyclocondensation (>95% regioselectivity), oxidative workup, and final cryogenic sieving/micronization operations. In-process process analytical technology (PAT) deployment includes near-infrared spectroscopy (NIR) for blend content uniformity monitoring (relative standard deviation <1.5%), Raman spectroscopy for polymorphic form confirmation during crystallization scale-up, and online HPLC reaction endpoint determination (>98% conversion). Final release testing encompasses potency assay (Karl Fischer water <0.4%, assay 98.0-102.0%), related substances evaluation (individual impurity <0.15%, total <0.5%), and physical characteristics verification (bulk density 0.45-0.55 g/mL, tapped density 0.60 g/mL). International Conference on Harmonisation (ICH) stability assessment generates comprehensive datasets confirming 60-month real-time shelf life under long-term conditions (25°C/60%RH) with accelerated Zone IVb predictions (40°C/75%RH/6 months exhibiting <1.0% degradation), photostability Option 2 compliance (<0.5% loss after 1.2 million lux-hours exposure), and freeze-thaw cycle robustness. Retained composite samples from each production lot enable retrospective re-analysis capabilities spanning seven years per pharmacopeial monographs. Electronic batch record management systems maintain 21 CFR Part 11 electronic signature compliance with comprehensive audit trail functionality, while serialized aggregation packaging (GS1 DataMatrix coding) supports full supply chain provenance verification from certificate of testing through end-user receipt protocols.

Safety, Handling & Laboratory Precautions

Laboratory handling of Bromonordiazepam Powder mandates exclusive use within certified chemical fume hoods maintaining minimum 100 linear feet per minute face velocity, complemented by personal protective equipment ensembles comprising 15-mil thickness nitrile gloves (chemical resistance rating Category A), ANSI Z87.1-compliant sealed safety goggles providing side shield protection, flame-resistant laboratory coats constructed from Nomex/cotton blends, and disposable N95 particulate respirators for aerosol-generating powder manipulations. Analytical weighing operations require static-dissipative microbalances equipped with ionizing air blowers neutralizing electrostatic charge buildup exceeding ±5 kV, conducted over secondary stainless steel containment trays preventing accidental dispersal. Storage segregation protocols isolate powder containers from incompatible reactive species including strong oxidizing agents (chromic acid, permanganates), acyl chlorides, and mineral acids within dedicated NFPA 30B-approved flammable materials cabinets featuring secondary spill containment capacity. Emergency spill response employs non-reactive diatomaceous earth sorbents followed by HEPA-filtered vacuum recovery (99.97% efficiency at 0.3 μm particles) and decontamination using 10% aqueous sodium bicarbonate solution under local exhaust ventilation. Material Safety Data Sheets delineate Globally Harmonized System (GHS) classifications encompassing Acute Toxicity Category 4 (oral/inhalation routes H302+H332), Skin Irritation Category 2 (H315), Serious Eye Damage Category 2B (H320), and specific precautionary statements (P261 avoid breathing dust, P280 wear protective gloves/eye protection, P305+P351+P338 if in eyes rinse cautiously with water).

Packaging, Labeling & Storage

Bromonordiazepam Powder packages in USP Type I clear borosilicate amber glass scintillation vials (20 mL capacity) secured with PTFE-faced silicone septa and open-hole polypropylene continuous thread closures incorporating integrated 1-gram silica gel Type 3A desiccant chambers maintaining equilibrium relative humidity below 15%. Primary containers feature induction heat-sealed aluminum foil liners providing tamper-evident oxygen and moisture barrier performance exceeding ASTM D4774 specifications. Secondary overwrap utilizes low-density polyethylene metallized Mylar pouches (12 μm aluminum vacuum deposition) achieving moisture vapor transmission rates below 0.02 g/m² per day at 38°C/90%RH. Globally Harmonized System-compliant labels prominently display CAS Registry Number 2894-61-3, ≥98% purity declaration, DOT UN3335 Other Regulated Material Surface Transportation identification, GHS exclamation mark health hazard pictogram (GHS07), standardized signal word “Warning,” and two-dimensional matrix barcodes linking to secure digital portals hosting batch-specific COAs, Safety Data Sheets, and raw analytical spectra. Recommended long-term storage employs -20°C to -80°C controlled-rate freezers under desiccated inert nitrogen atmosphere, validated stable exceeding 60 months by real-time ICH Q1A(R2) protocols; intermediate refrigerated storage (2-8°C) supports 36-month access periods while ambient controlled room temperature (15-25°C protected from light) permits 12-month handling. Photolytic stability testing confirms minimal degradation (<0.8%) following ICH Q1B Option 2 exposure conditions.

Intended Research Use & Market Positioning

Bromonordiazepam Powder finds primary application in forensic toxicology laboratories for quantitative confirmation of gidazepam metabolites (desalkylgidazepam ratios), LC-QqQ method validation establishing limits of quantitation below 0.5 ng/mL in postmortem blood and urine matrices, and high-resolution mass spectrometry library curation capturing diagnostic Br isotopic clusters and sequential neutral losses (CO, HNCO). Additional research utilities encompass solid-phase extraction optimization (>96% absolute recovery on HyperSep C18 Empore extraction disks), in vitro microsomal stability assessment (metabolic half-life determination), and quantitative structure-activity relationship modeling investigating 7-bromo electronic effects on GABA_A receptor subtype selectivity. Academic pharmacology departments leverage bulk powder for synthesis of isotopically labeled internal standards (13C6/D3 variants), while wastewater epidemiology programs achieve part-per-trillion sensitivity through online SPE preconcentration coupled with Orbitrap HRMS suspect screening workflows. Positioned strategically as a high-purity generic alternative to certified reference materials from national metrology institutes, Bromonordiazepam Powder delivers 55-70% procurement cost savings supporting high-volume proficiency testing schemes (z-scores consistently ≤1.5 across SWGDRUG/ECDD rounds) and regulatory compliance method transfers under ISO 17025 accreditation frameworks.

Ordering, Availability & Fulfillment

Bromonordiazepam Powder maintains perpetual ready-to-ship inventory enabling immediate order processing through PCI-DSS Level 1 compliant WooCommerce platforms supporting diverse global payment methodologies including major credit cards, ACH direct debit, SEPA transfers, and privacy-preserving cryptocurrency gateways. Orders received prior to 2 PM EST dispatch within 24 business hours utilizing temperature-controlled tracked carriers (DHL Express/FedEx Priority Overnight domestic, International Priority 2-5 days global) featuring plain exterior packaging ensuring discretion while maintaining complete customs declaration compliance with proforma invoices classifying HS Code 2933.99.9700 “Other Heterocyclic Compounds.” Volume-based tiered pricing activates at 5g (-12%), 25g (-22%), and 100g (-35%) thresholds; batch-specific Certificates of Analysis deliver automatically via secure encrypted portals within 4 hours of shipment confirmation. Dedicated institutional account management coordinates expedited COA rush delivery (<2 hours), hazardous materials preclearance documentation, and just-in-time inventory replenishment maintaining 99.4% order-to-ship on-time performance metrics.

Legal & Regulatory Disclaimer

Bromonordiazepam Powder (CAS 2894-61-3) distributed strictly and exclusively for legitimate laboratory research purposes only. Not for human consumption, veterinary applications, clinical trials, diagnostic procedures, therapeutic interventions, or any consumptive applications whatsoever. Purchasing entities and end-users assume complete and sole responsibility for ascertaining, verifying, and maintaining full compliance with all applicable local, national, international, and jurisdictional laws, regulations, import/export controls, and licensing requirements governing possession, handling, storage, transportation, and disposal of research chemicals. Seller disclaims all liability, warranties express or implied, extending to unauthorized, non-research applications, regulatory violations, or diversion activities; all sales subject to mandatory end-user verification, acceptable use attestation, and right of refusal without cause per Uniform Commercial Code §2-316(3)(b). Consult qualified legal counsel and pertinent jurisdictional authorities prior to acquisition; violations of stated terms immediately void all guarantees and indemnifications.